Oliveira Santos, MiguelOhana, BenjamimCarvalho, Mamede2022-09-082022-09-082017Clin Neurophysiol. 2017 Sep;128(9):1596-15981388-2457http://hdl.handle.net/10451/54388© 2017 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.Celiac disease (CD) is a chronic, multisystem and immunemediated disorder characterized by small-bowel sensitivity to dietary gluten and possibly other environmental factors in genetically predisposed individuals (Alaedini et al., 2002; Rigamonti et al., 2007; Caio et al., 2015). Recent growing evidence strongly suggests a correlation between anti-ganglioside antibodies and neurological syndromes in CD (Alaedini et al., 2002; Chin et al., 2003; Volta et al., 2006). One study showed that at least one type of anti-ganglioside antibody (anti-GM1, GM2, GD1a or GD1b antibodies) was detected in six of twenty-seven CD patients, and all of them had peripheral nerve involvement (Alaedini et al., 2002). Chin et al., (2003) have also found anti-ganglioside antibodies in up to 65% of CD patients with peripheral neuropathy. About 10% of patients with CD have neurological symptoms (Alaedini et al., 2002; Chin et al., 2003; Rigamonti et al., 2007; Caio et al., 2015), but no association to multifocal acquired motor axonopathy (MAMA) has been previously reported.engjournal article10.1016/j.clinph.2017.06.0381872-8952